Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

Feijoo, Samantha; Vilaseca Jolonch, Andreu; Ariño, Helena; IACOBONI, GLORIA; Zabalza, Ana; Fissolo, Nicolás Miguel; AREVALO, MARIA JESUS; Cecilia del Carmen, Carpio Segura; Sanchez-Salinas, Mario Andrés; Tintore, Mar; Comabella Lopez, Manuel; Barba, Pere; Vidal-Jordana, Angela; Montalban, Xavier

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

CAR‐T cells; Autoimmune neurology; Biomarker

Detalles Bibliográficos
Autores:	Feijoo, Samantha, Vilaseca Jolonch, Andreu, Ariño, Helena, IACOBONI, GLORIA, Zabalza, Ana, Fissolo, Nicolás Miguel, AREVALO, MARIA JESUS, Cecilia del Carmen, Carpio Segura, Sanchez-Salinas, Mario Andrés, Tintore, Mar, Comabella Lopez, Manuel, Barba, Pere, Vidal-Jordana, Angela, Montalban, Xavier
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2025
País:	España
Institución:	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:	Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:	oai:recercat.cat:11351/13761
Acceso en línea:	http://hdl.handle.net/11351/13761
Access Level:	acceso abierto
Palabra clave:	Marcadors bioquímics Filaments citoplasmàtics Neurotoxicologia Sistema nerviós - Malalties - Diagnòstic Immunoteràpia Teràpia cel·lular ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Biological Factors::Biomarkers CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins DISEASES::Nervous System Diseases::Neurotoxicity Syndromes Other subheadings::Other subheadings::/diagnosis TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos ENFERMEDADES::enfermedades del sistema nervioso::síndromes de neurotoxicidad Otros calificadores::Otros calificadores::/diagnóstico

id	ES_f11eb84d98bf44d29461fc353d7d93c0
oai_identifier_str	oai:recercat.cat:11351/13761
network_acronym_str	ES
network_name_str	España
repository_id_str
dc.title.none.fl_str_mv	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
title	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
spellingShingle	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy Feijoo, Samantha Marcadors bioquímics Filaments citoplasmàtics Neurotoxicologia Sistema nerviós - Malalties - Diagnòstic Immunoteràpia Teràpia cel·lular ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Biological Factors::Biomarkers CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins DISEASES::Nervous System Diseases::Neurotoxicity Syndromes Other subheadings::Other subheadings::/diagnosis TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos ENFERMEDADES::enfermedades del sistema nervioso::síndromes de neurotoxicidad Otros calificadores::Otros calificadores::/diagnóstico
title_short	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
title_full	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
title_fullStr	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
title_full_unstemmed	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
title_sort	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy
dc.creator.none.fl_str_mv	Feijoo, Samantha Vilaseca Jolonch, Andreu Ariño, Helena IACOBONI, GLORIA Zabalza, Ana Fissolo, Nicolás Miguel AREVALO, MARIA JESUS Cecilia del Carmen, Carpio Segura Sanchez-Salinas, Mario Andrés Tintore, Mar Comabella Lopez, Manuel Barba, Pere Vidal-Jordana, Angela Montalban, Xavier
author	Feijoo, Samantha
author_facet	Feijoo, Samantha Vilaseca Jolonch, Andreu Ariño, Helena IACOBONI, GLORIA Zabalza, Ana Fissolo, Nicolás Miguel AREVALO, MARIA JESUS Cecilia del Carmen, Carpio Segura Sanchez-Salinas, Mario Andrés Tintore, Mar Comabella Lopez, Manuel Barba, Pere Vidal-Jordana, Angela Montalban, Xavier
author_role	author
author2	Vilaseca Jolonch, Andreu Ariño, Helena IACOBONI, GLORIA Zabalza, Ana Fissolo, Nicolás Miguel AREVALO, MARIA JESUS Cecilia del Carmen, Carpio Segura Sanchez-Salinas, Mario Andrés Tintore, Mar Comabella Lopez, Manuel Barba, Pere Vidal-Jordana, Angela Montalban, Xavier
author2_role	author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Institut Català de la Salut [Vilaseca A, Ariño H, Zabalza A, Fissolo N, Arévalo MJ, Comabella M, Vidal-Jordana Á] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Iacoboni G, Feijóo S, Carpio C, Sánchez M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tintoré M, Montalban X] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Universitat de Vic-Universitat Central de Catatlunya (UVic-UCC), Vic, Spain. [Barba P] Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv	Marcadors bioquímics Filaments citoplasmàtics Neurotoxicologia Sistema nerviós - Malalties - Diagnòstic Immunoteràpia Teràpia cel·lular ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Biological Factors::Biomarkers CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins DISEASES::Nervous System Diseases::Neurotoxicity Syndromes Other subheadings::Other subheadings::/diagnosis TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos ENFERMEDADES::enfermedades del sistema nervioso::síndromes de neurotoxicidad Otros calificadores::Otros calificadores::/diagnóstico
topic	Marcadors bioquímics Filaments citoplasmàtics Neurotoxicologia Sistema nerviós - Malalties - Diagnòstic Immunoteràpia Teràpia cel·lular ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Biological Factors::Biomarkers CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins DISEASES::Nervous System Diseases::Neurotoxicity Syndromes Other subheadings::Other subheadings::/diagnosis TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos ENFERMEDADES::enfermedades del sistema nervioso::síndromes de neurotoxicidad Otros calificadores::Otros calificadores::/diagnóstico
description	CAR‐T cells; Autoimmune neurology; Biomarker
publishDate	2025
dc.date.none.fl_str_mv	2025 2025 2025
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11351/13761
url	http://hdl.handle.net/11351/13761
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	European Journal of Neurology;32(8) https://doi.org/10.1111/ene.70305
dc.rights.none.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Wiley
publisher.none.fl_str_mv	Wiley
dc.source.none.fl_str_mv	Scientia reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str	Recercat. Dipósit de la Recerca de Catalunya
collection	Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869424098789031936
spelling	Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell TherapyFeijoo, SamanthaVilaseca Jolonch, AndreuAriño, HelenaIACOBONI, GLORIAZabalza, AnaFissolo, Nicolás MiguelAREVALO, MARIA JESUSCecilia del Carmen, Carpio SeguraSanchez-Salinas, Mario AndrésTintore, MarComabella Lopez, ManuelBarba, PereVidal-Jordana, AngelaMontalban, XavierMarcadors bioquímicsFilaments citoplasmàticsNeurotoxicologiaSistema nerviós - Malalties - DiagnòsticImmunoteràpiaTeràpia cel·lularANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, AdoptiveOther subheadings::Other subheadings::Other subheadings::/adverse effectsCHEMICALS AND DRUGS::Biological Factors::BiomarkersCHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament ProteinsDISEASES::Nervous System Diseases::Neurotoxicity SyndromesOther subheadings::Other subheadings::/diagnosisTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptivaOtros calificadores::Otros calificadores::Otros calificadores::/efectos adversosCOMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadoresCOMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentosENFERMEDADES::enfermedades del sistema nervioso::síndromes de neurotoxicidadOtros calificadores::Otros calificadores::/diagnósticoCAR‐T cells; Autoimmune neurology; BiomarkerCèl·lules CAR-T; Neurologia autoimmune; BiomarcadorCélulas CAR-T; Neurología autoinmune; BiomarcadorBackground and Objectives Immune effector cell-associated neurotoxicity syndrome (ICANS) is a potential complication following Chimeric Antigen Receptor (CAR) T-cell infusion. Biomarkers to aid in early diagnosis and severity assessment are lacking. We aim to describe and compare serum neurofilament light chain (sNfL) dynamics in non-Hodgkin lymphoma (NHL) patients undergoing anti-CD19 CAR T-cell therapy, based on ICANS presence and severity. Methods This is a case–control study nested within a cohort of NHL patients treated with anti-CD19 CAR T-cells at a tertiary care center. From this cohort, we selected those who developed ICANS and had available blood samples. These patients were compared to matched NHL patients without ICANS from the same cohort. sNfL concentrations were measured immediately pre-infusion and on days 7 and 14 post-infusion, with z-scores calculated against a normative database. Mixed linear and ROC analysis assessed sNfL dynamics by ICANS presence and severity. Results Of 159 patients treated, 54 (34%) developed ICANS. We included 32 patients with ICANS and 22 matched controls. Baseline sNfL concentrations were similarly elevated in both ICANS and non-ICANS patients. However, on day 7, patients with moderate–severe ICANS (grade ≥ 2) had higher sNfL levels (median z-score 2.33) than those with mild or no ICANS (median z-score 1.72;p = 0.022). The optimal cutoff to discriminate moderate–severe ICANS from other patients based on sNfL was a z-score of 2.14 on day 7 (p = 0.004). Discussion Moderate–severe ICANS is associated with elevated sNfL levels by day 7 post-infusion, indicating early neuroaxonal damage and underscoring sNfL as a valuable biomarker for assessing ICANS severity.WileyInstitut Català de la Salut[Vilaseca A, Ariño H, Zabalza A, Fissolo N, Arévalo MJ, Comabella M, Vidal-Jordana Á] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Iacoboni G, Feijóo S, Carpio C, Sánchez M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tintoré M, Montalban X] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Universitat de Vic-Universitat Central de Catatlunya (UVic-UCC), Vic, Spain. [Barba P] Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/11351/13761Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésEuropean Journal of Neurology;32(8)https://doi.org/10.1111/ene.70305Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/137612026-05-29T05:05:01Z
score	15.812455

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

Similares en LA Referencia